The proposed project will be performed under the mentorship of Dr. Ravi Salgia, who has great expertise in the tyrosine kinases, cytoskeleton, and invasion/metastasis in SCLC. My long term career goal is to become an independent clinician-scientist in translational cancer research with focus on targeted therapeutics. I have found that c-Met is expressed, functional and sometimes mutated in SCLC. I have novel immunohistochemistry finding of the activated phospho-Met localized preferentially at the tumor invasive front. In the recently completed c-Met mutational analysis in SCLC, I have identified novel alternatively spliced transcripts and somatic mutations of c-Met, particularly in the Sema domain and the juxtamembrane (JM) domain. The JM-mutations were found to alter c-Met signaling with increased tyrosine phosphorylation including the key focal adhesion protein paxillin. This was found correlating with enhanced tumorigenesis and cell motility/migration by the JM mutations. These results suggest a unique role of the JM-domain in c-Met signaling with dramatic effects in cytoskeletal functions. Preliminary studies with two available specific c-Met inhibitors (SU11274 and PHA665752) have shown promising inhibition of viability and motility of SCLC. I now aim to further determine the functional implications of the various c-Met mutations in SCLC, such as viability, survival/ apoptosis, and transformation. Effects of the c-Met mutations on the downstream PI3K/Akt signaling pathway would be determined with combinations of PI3K-kinase assay, IP/IB, and also PI3K inhibitors. Cell lines expressing wild-type or mutated Met would be established and utilized in functional analyses. Various biological assays, such as scattering, motility/migration, and invasion would be investigated. Utilizing phosphospecific antibodies against focal adhesion proteins, and time-lapse video-microscopy, studies would be focused on cytoskeletal functions. The role of various inhibitors of c-Met and its mutants in SCLC would be further defined aiming to translate into novel targeted-therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA102545-02
Application #
7125145
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
2005-09-22
Project End
2010-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2006
Total Cost
$131,057
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Fan, Weiwen; Tang, Zhe; Yin, Lihong et al. (2011) MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res 71:4494-505
Wang, Jun; Ramakrishnan, Ramesh; Tang, Zhe et al. (2010) Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem 56:623-32
Wu, Chunying; Tang, Zhe; Fan, Weiwen et al. (2010) In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor. J Med Chem 53:139-46
Tang, Z; Jiang, S; Du, R et al. (2009) Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene 28:518-33
Tang, Z; Du, R; Jiang, S et al. (2008) Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99:911-22
Ma, Patrick C; Tretiakova, Maria S; MacKinnon, Alexander C et al. (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47:1025-37
Ma, P C; Tretiakova, M S; Nallasura, V et al. (2007) Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97:368-77
Bharti, Ajit; Ma, Patrick C; Salgia, Ravi (2007) Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev 26:451-66
Ma, Patrick C; Zhang, Xiaodong; Wang, Zhenghe J (2006) High-throughput mutational analysis of the human cancer genome. Pharmacogenomics 7:597-612